Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
71°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SQZ Biotechnologies Company
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
February 29, 2024
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
OTC
SQZB
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
November 08, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
OTC
SQZB
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
November 03, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
OTC
SQZB
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
August 10, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
OTC
SQZB
SQZ Biotechnologies Provides Update on Collaboration with Roche
July 25, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
OTC
SQZB
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
June 15, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
May 10, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
March 22, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
March 22, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
December 06, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
October 03, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
September 12, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at Upcoming Investor Conferences
September 07, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Leadership Transition
September 06, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
July 12, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
June 21, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
June 16, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient
December 09, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose
December 02, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China
December 01, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference
November 15, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio Updates
November 10, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor
June 23, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors
June 04, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotech to Present at Jefferies Virtual Health Care Conference
May 27, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors
May 19, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 11, 2021
From
SQZ Biotechnologies Company
Via
Business Wire
Tickers
SQZ
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.